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The Editorial on the Research Topic
Antifungal Drug Discovery: New Theories and New Therapies
Medically important fungal infections can be broadly classified into superficial surface infections
and invasivemycoses (Samaranayake andMacFarlane, 1990; Roemer and Krysan, 2014). Superficial
surface infections include mucosal candidiasis, dermatophyte infections whereas invasive mycoses
affect sterile body sites such as bloodstream, central nervous system, kidney, lungs, and liver. Rise
of fungal infections has caused a substantial morbidity and mortality globally (Vallabhaneni et al.,
2016). It is reported that mortality among patients with invasive candidiasis is as high as 40%, even
when patients receive antifungal therapy (Kullberg and Arendrup, 2015).
Antifungal drugs are relatively difficult to develop compared to antibacterial drugs owing to
the eukaryotic nature of the cells. Only a few classes of antifungal drugs, such as polyenes, azoles,
echinocandins, allylamines, and flucytosine, are available to treat the myriad of fungal infections
(Sanglard et al., 2009). Of the current antifungal agents, none have all the characteristics of an ideal
agent (Wong et al., 2014). Antifungal resistance and host-related adverse reactions further limit the
existing antifungal arsenal against fungal pathogens (Chandrasekar, 2011). Rising drug resistance is
an inevitable problem, particularly for fluconazole, a drug of choice for candidiasis in AIDS patients
(Siikala et al., 2010; Rautemaa and Ramage, 2011). Drug resistance has also been reported for
recently introduced echinocandin antifungal agents (Seneviratne et al., 2008a; Ben-Ami et al., 2011;
Clancy and Nguyen, 2011). Moreover, some fungal species are inherently resistance to existing
antifungals (Sanglard; Kołaczkowska and Kołaczkowski, 2016). In addition, biofilmmode of fungal
growth is known to be highly resistant to antifungal agents (Chandra et al., 2005; Seneviratne et al.,
2008b). Hence, the development of more effective and safe antifungal agents is a top priority in
the health care field. Therefore, this special research topic aimed to address the new theories and
therapies pertaining to antifungal drug discovery, covering aspects of clinical relevance and novel
antifungal strategies.
Majority of the articles published under this research topic belongs to the Candida species,
which is a group of major fungal pathogens in humans. Candida species are commensal fungi
that inhabit various niches of the human body, including the oral cavity, gastrointestinal tract,
vagina, and skin (Samaranayake andMacFarlane, 1990; Mayer et al., 2013). However, under certain
circumstances, Candida can cause infections, or candidiasis, ranging from superficial mucous
membrane infections to life-threatening systemic diseases. Candida albicans is the most prevalent
fungal pathogen in lethal blood stream infections of humans (Seneviratne et al., 2011). C. albicans
infections are a significant clinical problem especially in compromised host populations undergoing
HIV/AIDS treatment, chemotherapy or organ transplantation. Moreover, sharp increase in aging
populations which are susceptible to fungal infections is expected in the next few decades. The
currently available antifungal agents are not always effective against C. albicans, which remains
a ubiquitous pathogen in nosocomial diseases, causing severe mucosal infections such as oral
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candidiasis, onycomycoses, vulvovaginal candidiasis, and
systemicmycoses with highmortality rates (Kojic andDarouiche,
2004; Zaoutis et al., 2005; Concia et al., 2009).
At the start of the research topic, clinical relevance of oral
candidiasis has been discussed in order to provide a glimpse
of human fungal infections (Patil et al.). Biofilm formation of
the fungal pathogen is a significant problem in medical-device
associated infections and directly related to therapeutic failure
(Williams and Ramage, 2015). As conventional antifungal agents
are ineffective against fungal biofilms, alternative strategies are
needed. Novel antifungal compounds that target fungal biofilm
formation and the host inflammatory response such as myriocin,
fulvic acid, and acetylcholine have been discussed in the research
topic as candidate dual action therapeutics to treat opportunistic
fungal infections (Borghi et al.). Microbial biotransformation has
emerged as an important tool for obtaining novel substances
which possess antifungal activity. Implication of endophytic
fungi as cell factories for producing new antifungal molecules
and in silico approach using databases of 3Dmolecular structures
are also discussed (Bianchini et al.). Oshima and colleagues
introduce an interesting concept of biogenics for oral candidiasis.
Biogenics advocates the use of beneficial bioactive substances
produced by probiotic bacteria, whose activities are independent
of the viability of probiotic bacteria in human bodies. Ravikumar
and colleagues examine various immune-enhancing strategies for
the invasive fungal diseases caused by Candida and Aspergillus
species. These novel approaches include cytokine therapy,
granulocyte transfusion, antibody-based therapy, natural killer
cell treatment and adoptive T cell transfer. Molecules such
as phenolic compounds, derived from natural sources and
exhibiting considerable antifungal properties are a source for
the development of novel anti-candidal therapy (Teodoro et al.).
Therefore, potential use, proposed mechanisms of action and
limitations of phenolic acids have been discussed.
Candida bloodstream isolates derived from Hong Kong
have shown to possess virulence attributes such as biofilm
formation, hemolysin production, proteinase activity as well
as perturbations in their antifungal sensitivity in the presence
of serum, which may contribute to treatment complication in
candidemia (Seneviratne et al.). One of the major mechanisms
contributing to multi-drug resistance in C. albicans is the
plasma membrane drug-eﬄux system. Therefore, application
of inhibitors of drug-eﬄux pumps has been suggested as a
strategy to increase the susceptibility of C. albicans to antifungals.
Szczepaniak et al. developed a new fluorescence method that
allows in vivo activity evaluation of compounds inhibiting
C. albicans transporters. They demonstrated that fluorescence
labeling with diS-C3(3) potentiometric dye enables a real-time
observation of the activity of C. albicans Cdr1 and Cdr2
transporters. The new method was able to demonstrate the
different specificities of enniatin A and beauvericin toward drug-
eﬄux pumps. In another study investigators have developed three
structurally related chemo-sensititzers i.e., oxathiolone fused
chalcone derivatives to successfully restore the sensitivity of
fluconazole resistantC. albicans strains. Themechanism of action
is a possible non-competitive inhibition of drug-eﬄux pumps
Mdr1, Cdr1, and Cdr2. However, more research is warranted
in this area to fully establish the role of chemo-sensitizers in
clinical use.
Antimicrobial peptide isolates from various sources are
also a promising source to develop novel antimycotic agents.
A study under this research topic has shown anti-Candida
activity of antimicrobial peptide produced by Enterococcus
faecium (Roy et al.). It appears to target chitin in the cell
wall of Candida species. Host derived molecules like histatin
5 protects human oral mucosa against the transformation
of commensal C. albicans into a pathogenic invader. A
work by Moffa and colleagues demonstrated that coating
with histatin 5 reduces C. albicans colonization of epithelial
cell surfaces and also protects the basal cell layers from
undergoing apoptosis. Hence, there is a possibility of using
host derived antifungal molecules to prevent Candida
infections, which may be a useful strategy in compromised host
populations.
Candida glabrata is an emerging human fungal pathogen.
A study examined the role of glucose sensing mechanism in
C. glabrata using SNF3 (Sucrose Non Fermenting 3) knockout
strains. Mutation results in higher susceptibility to amphotericin
B in low glucose environment (0.1%), but showed no effect on
biofilm formation capability. Going beyond Candida species, a
study of dermatophyte fungus Trichophyton rubrum investigated
the role of Hsp90 in its pathogenicity and drug susceptibility.
Chemical inhibition of Hsp90 resulted in increased susceptibility
of the fungus to itraconazole and micafungin. The synergism
observed between the inhibition of Hsp90 and the effect of
itraconazole or micafungin in reducing the fungal growth is
of great interest as a novel and potential strategy to treat
dermatophytoses.
This specific research topic on antifungal drug discovery
provides a detailed overview of potential novel antifungal
strategies, promising new discoveries and their clinical
implications, particularly that of Candida species.
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